Walvax’s modular workshop for SARS-CoV-2 mRNA Vaccine, the first modular mRNA workshop in China, has been delivered
Media
Sep 7, 2021
Walvax
On September 1, 2021, Walvax’s modular workshop for SARS-CoV-2 mRNA Vaccine, was officially delivered. It is an advanced process combining modular buildings with conventionally built facilities, which allows for tighter construction and can accelerate the industrialization schedule of SARS-CoV-2 mRNA Vaccine. Construction of modular buildings can occur simultaneously with the site and foundation work, allowing projects to be completed in a shorter period.
Related Links
Apr 14, 2023
Walvax publishes safety and preliminary immunogenicity results from the Phase 1 trial of its bivalent HPV vaccine Walrinvax™ in journal Vaccine
Learn More
May 19, 2023
Walvax’s PCV13-TT Receives Endorsement from the Pediatric Infectious Disease Society of Thailand
Learn More
Feb 8, 2022
CEPI, Shanghai Zerun Biotech and Walvax Biotech expand collaboration to develop COVID-19 multi-variant vaccine
Learn More